Oncology & Cancer

Outcomes steadily improve for multiple myeloma treated with ASCT

(HealthDay)—For patients with multiple myeloma (MM) treated with autologous stem cell transplantation (ASCT), long-term outcomes have improved steadily, according to a study published in the Jan. 28 issue of Blood Advances.

Oncology & Cancer

New CAR-T target yields promising results for multiple myeloma

Too many patients with cancers like multiple myeloma relapse after treatment. This grim reality motivated researchers at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) to try to improve the depth and durability ...

Oncology & Cancer

Frailty score may predict outcomes in multiple myeloma

(HealthDay)—A frailty scale that includes Eastern Cooperative Oncology Group performance status (ECOG PS) may predict outcomes for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM), according to ...

page 1 from 28

Multiple myeloma

Multiple myeloma (from myelo-, bone marrow), also known as MM, myeloma, plasma cell myeloma, or as Kahler's disease (after Otto Kahler) is a cancer of the white blood cells known as plasma cells, which produce antibodies.

These plasma cells, or B cells, are part of the immune system, formed in bone marrow, and numerous in lymphatics. Myeloma is incurable, but remissions may be induced with steroids, chemotherapy, thalidomide and stem cell transplants.

There were 15,270 cases diagnosed and 11,070 deaths in the United States in 2004, and an incidence of 4/100,000 worldwide. Median survival is 50–55 months. Chromosome diagnosis can separate patients into more or less favorable prognoses.

Myeloma is part of the broad group of diseases called hematological malignancies.

This text uses material from Wikipedia, licensed under CC BY-SA